InvestorsHub Logo
Followers 121
Posts 17456
Boards Moderated 0
Alias Born 01/06/2014

Re: fsulevine post# 110542

Friday, 07/21/2017 10:27:22 AM

Friday, July 21, 2017 10:27:22 AM

Post# of 424188
"If they found 20% more cardiovascular events occurring in the drug group as opposed to the placebo, they would stop it for safety concerns"

How could they find such if they do not see UNBLINDED CV data? This is my exact point, the only way for them to know if 20% (or whatever number) more events occur in the active (drug) arm is if they UNBLIND the CV data.

If they don't unblind it, there is no way for them to know which arm is causing more events.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News